The role and mechanism of the gut microbiota in the development and treatment of diabetic kidney disease

作者全名："Wu, Xiaofang; Zhao, Lei; Zhang, Yujiang; Li, Kailong; Yang, Jurong"

作者地址："[Wu, Xiaofang; Zhao, Lei; Li, Kailong; Yang, Jurong] Chongqing Med Univ, Affiliated Hosp 3, Dept Nephrol, Chongqing, Peoples R China; [Zhang, Yujiang] Chongqing Jiangjin Second Peoples Hosp, Dept Nephrol, Chongqing, Peoples R China"

通信作者："Yang, JR (通讯作者)，Chongqing Med Univ, Affiliated Hosp 3, Dept Nephrol, Chongqing, Peoples R China."

来源：FRONTIERS IN PHYSIOLOGY

ESI学科分类：BIOLOGY & BIOCHEMISTRY

WOS号：WOS:000982020800001

JCR分区：Q2

影响因子：3.2

年份：2023

卷号：14

期号：　

开始页：　

结束页：　

文献类型：Review

关键词：gut microbiota; diabetic kidney disease; inflammation; immunity; oxidative stress; gut microbiota-targeted therapies

摘要："Diabetic kidney disease (DKD) is a common complication in patients with diabetes mellitus (DM). Increasing evidence suggested that the gut microbiota participates in the progression of DKD, which is involved in insulin resistance, renin-angiotensin system (RAS) activation, oxidative stress, inflammation and immunity. Gut microbiota-targeted therapies including dietary fiber, supplementation with probiotics or prebiotics, fecal microbiota transplantation and diabetic agents that modulate the gut microbiota, such as metformin, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-glucose transporter-2 (SGLT-2) inhibitors. In this review, we summarize the most important findings about the role of the gut microbiota in the pathogenesis of DKD and the application of gut microbiota-targeted therapies."

基金机构：National Natural Science Foundation of China [82270723]; Chongqing Talent Program Project [cstc2021ycjh-bgzxm0090]

基金资助正文：This work was funded by the National Natural Science Foundation of China (No. 82270723) and the Chongqing Talent Program Project (cstc2021ycjh-bgzxm0090).